• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Direct medical cost of diabetes in rural China using electronic insurance claims data and diabetes management data.中国农村糖尿病的直接医疗费用:基于电子保险理赔数据和糖尿病管理数据的分析。
J Diabetes Investig. 2019 Mar;10(2):531-538. doi: 10.1111/jdi.12897. Epub 2018 Aug 17.
2
How do type 2 diabetes mellitus (T2DM)-related complications and socioeconomic factors impact direct medical costs? A cross-sectional study in rural Southeast China.2 型糖尿病(T2DM)相关并发症和社会经济因素如何影响直接医疗费用?中国东南部农村的一项横断面研究。
BMJ Open. 2018 Nov 1;8(11):e020647. doi: 10.1136/bmjopen-2017-020647.
3
How do type 2 diabetes mellitus-related chronic complications impact direct medical cost in four major cities of urban China?中国城市四大主要城市中,2型糖尿病相关慢性并发症如何影响直接医疗费用?
Value Health. 2009 Sep;12(6):923-9. doi: 10.1111/j.1524-4733.2009.00561.x.
4
Changes in Direct Medical Cost and Medications for Managing Diabetes in Beijing, China, 2016 to 2018: Electronic Insurance Data Analysis.2016 年至 2018 年中国北京糖尿病管理的直接医疗费用和药物变化:电子保险数据分析。
Ann Fam Med. 2021 Jul-Aug;19(4):332-341. doi: 10.1370/afm.2686.
5
Assessment of hospital length of stay and direct costs of type 2 diabetes in Hubei Province, China.中国湖北省2型糖尿病患者住院时间及直接费用评估。
BMC Health Serv Res. 2017 Mar 14;17(1):199. doi: 10.1186/s12913-017-2140-4.
6
Economic costs of diabetes in the U.S. In 2007.2007年美国糖尿病的经济成本。
Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017.
7
Association between provider specialty and healthcare costs and glycemic control for patients with diabetes.糖尿病患者的医疗服务提供者专业与医疗费用及血糖控制之间的关联
J Med Econ. 2018 Jul;21(7):704-708. doi: 10.1080/13696998.2018.1467324. Epub 2018 May 17.
8
The impact of diabetes mellitus on healthcare costs in Italy.糖尿病对意大利医疗成本的影响。
Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):709-19. doi: 10.1586/erp.11.78.
9
Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania.立陶宛2型糖尿病患者医疗保健及其并发症的直接成本。
Medicina (Kaunas). 2014;50(1):54-60. doi: 10.1016/j.medici.2014.05.007. Epub 2014 Jun 14.
10
[Survey of economic burden of hepatitis B-related diseases in 12 areas in China].[中国12个地区乙肝相关疾病经济负担调查]
Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Jul 10;38(7):868-876. doi: 10.3760/cma.j.issn.0254-6450.2017.07.005.

引用本文的文献

1
Economic costs and medications for diabetes in older patients in Beijing, China: electronic insurance data analysis.中国北京老年患者糖尿病的经济成本与药物治疗:电子保险数据分析
Front Pharmacol. 2025 Apr 7;16:1549244. doi: 10.3389/fphar.2025.1549244. eCollection 2025.
2
The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.在中国,每周一次司美格鲁肽与西格列汀治疗2型糖尿病的长期成本效益分析。
Health Econ Rev. 2024 Apr 2;14(1):26. doi: 10.1186/s13561-024-00499-2.
3
A health economic analysis of an integrated diabetes care program in China: based on real-world evidence.中国综合糖尿病护理项目的卫生经济学分析:基于真实世界证据。
Front Public Health. 2023 Dec 19;11:1211671. doi: 10.3389/fpubh.2023.1211671. eCollection 2023.
4
Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide.在中国,共享照护模式对于慢性乙型肝炎的管理极具成效且具有成本效益:重新诠释初级保健与专科医疗的划分
Lancet Reg Health West Pac. 2023 Mar 20;35:100737. doi: 10.1016/j.lanwpc.2023.100737. eCollection 2023 Jun.
5
Trends in economic burden of type 2 diabetes in China: Based on longitudinal claim data.中国 2 型糖尿病经济负担的变化趋势:基于纵向索赔数据。
Front Public Health. 2023 Apr 18;11:1062903. doi: 10.3389/fpubh.2023.1062903. eCollection 2023.
6
The clinical characteristics of Chinese elderly patients with different durations of type 2 diabetes mellitus.中国老年 2 型糖尿病患者不同病程的临床特征。
Front Endocrinol (Lausanne). 2022 Jul 29;13:904347. doi: 10.3389/fendo.2022.904347. eCollection 2022.
7
Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.在中国,接受以二甲双胍为基础背景治疗的2型糖尿病患者使用司美格鲁肽、度拉糖肽和艾塞那肽每周一次治疗的成本-效用分析
Front Pharmacol. 2022 Feb 18;13:831364. doi: 10.3389/fphar.2022.831364. eCollection 2022.
8
What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China.中国2型糖尿病患者在选择二线降糖药物时最看重的因素
Front Pharmacol. 2021 Dec 23;12:802897. doi: 10.3389/fphar.2021.802897. eCollection 2021.
9
Artificial Intelligence-Based Diagnosis of Diabetes Mellitus: Combining Fundus Photography with Traditional Chinese Medicine Diagnostic Methodology.基于人工智能的糖尿病诊断:眼底摄影与中医诊断方法相结合。
Biomed Res Int. 2021 Apr 20;2021:5556057. doi: 10.1155/2021/5556057. eCollection 2021.
10
Association between social determinants of health and direct economic burden on middle-aged and elderly individuals living with diabetes in China.中国中老年糖尿病患者健康社会决定因素与直接经济负担的关系。
PLoS One. 2021 Apr 15;16(4):e0250200. doi: 10.1371/journal.pone.0250200. eCollection 2021.

本文引用的文献

1
DIRECT COSTS OF TYPE 2 DIABETES: A BRAZILIAN COST-OF-ILLNESS STUDY.2 型糖尿病的直接成本:一项巴西疾病成本研究。
Int J Technol Assess Health Care. 2018 Jan;34(2):180-188. doi: 10.1017/S026646231800017X. Epub 2018 Apr 10.
2
Cost of diabetes mellitus in Africa: a systematic review of existing literature.非洲的糖尿病医疗成本:现有文献的系统综述。
Global Health. 2018 Jan 16;14(1):3. doi: 10.1186/s12992-017-0318-5.
3
Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013.2013年中国糖尿病及糖尿病前期的患病率与民族分布特征
JAMA. 2017 Jun 27;317(24):2515-2523. doi: 10.1001/jama.2017.7596.
4
Revealing the cost of Type II diabetes in Europe.揭示欧洲 II 型糖尿病的成本。
Diabetologia. 2002 Jul;45(Suppl 1):S5-S12. doi: 10.1007/s00125-002-0858-x.
5
Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies.德国2型糖尿病的成本负担:基于人群的KORA研究结果
BMJ Open. 2016 Nov 21;6(11):e012527. doi: 10.1136/bmjopen-2016-012527.
6
Trends in health care expenditure in U.S. adults with diabetes: 2002-2011.2002 - 2011年美国成年糖尿病患者的医疗保健支出趋势
Diabetes Care. 2015 Oct;38(10):1844-51. doi: 10.2337/dc15-0369. Epub 2015 Jul 22.
7
Direct medical cost of type 2 diabetes in singapore.新加坡2型糖尿病的直接医疗费用。
PLoS One. 2015 Mar 27;10(3):e0122795. doi: 10.1371/journal.pone.0122795. eCollection 2015.
8
A systematic review of the direct economic burden of type 2 diabetes in china.中国 2 型糖尿病直接经济负担的系统评价。
Diabetes Ther. 2015 Mar;6(1):7-16. doi: 10.1007/s13300-015-0096-0. Epub 2015 Feb 5.
9
The lifetime cost of diabetes and its implications for diabetes prevention.糖尿病的终身成本及其对糖尿病预防的影响。
Diabetes Care. 2014 Sep;37(9):2557-64. doi: 10.2337/dc13-2484.
10
Health-care cost of diabetes in South India: A cost of illness study.印度南部糖尿病的医疗保健成本:一项疾病成本研究。
J Res Pharm Pract. 2013 Jul;2(3):114-7. doi: 10.4103/2279-042X.122382.

中国农村糖尿病的直接医疗费用:基于电子保险理赔数据和糖尿病管理数据的分析。

Direct medical cost of diabetes in rural China using electronic insurance claims data and diabetes management data.

机构信息

Department of NCDs Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.

Shorenstein Asia-Pacific Research Center, Stanford University, Stanford, California, USA.

出版信息

J Diabetes Investig. 2019 Mar;10(2):531-538. doi: 10.1111/jdi.12897. Epub 2018 Aug 17.

DOI:10.1111/jdi.12897
PMID:29993198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6400160/
Abstract

AIMS/INTRODUCTION: To evaluate the annual direct medical cost attributable to type 2 diabetes mellitus according to socioeconomic factors, medical conditions and complications categories.

MATERIALS AND METHODS

We created uniquely detailed data from merging datasets of the local diabetes management system and the social security system in Tongxiang, China. We calculated the type 2 diabetes mellitus-related total cost and out-of-pocket cost for inpatient admissions and outpatient visits, and compared the cost for patients with or without complications by different healthcare items.

RESULTS

A total of 16,675 patients were eligible for analysis. The type 2 diabetes mellitus-related cost accounted for 40.6% of the overall cost. The cost per patient was estimated to be a median of 1,067 Chinese Yuan, 7,114 Chinese Yuan and 969 Chinese Yuan for inpatient and outpatient cost, respectively. The median total cost for hospital-based care was 3.69-fold higher than that for primary care. The median cost of patients with complications was 3.46-fold higher than that of those without complications. The median cost for a patient with only macrovascular, only microvascular or both macrovascular and microvascular complications were 3.13-, 3.79- and 10.95-fold higher than that of patients without complications. Pharmaceutical expenditure accounted for 51.8 and 79.7% of the total cost for patients with or without complications, respectively.

CONCLUSIONS

Although the type 2 diabetes mellitus-related cost per patient was relatively low, it accounted for a great proportion of the overall cost. Complications obviously aggravated the economic burden of type 2 diabetes mellitus. Proper management and the prevention of diabetes and its complications are urgently required to curtail the economic burden.

摘要

目的/引言:评估 2 型糖尿病患者的年度直接医疗费用,分析其与社会经济因素、医疗状况和并发症类别的关系。

材料与方法

我们整合了中国桐乡地区糖尿病管理系统和社会保障系统的数据,创建了详细的独特数据集。我们计算了 2 型糖尿病患者住院和门诊的总费用和自付费用,并根据不同的医疗项目比较了有或无并发症患者的费用。

结果

共有 16675 名患者符合分析条件。2 型糖尿病相关费用占总费用的 40.6%。每位患者的费用估计中位数为 1067 元人民币,用于住院和门诊费用分别为 7114 元和 969 元人民币。基于医院的护理总成本是初级保健的 3.69 倍。有并发症患者的总费用中位数是无并发症患者的 3.46 倍。仅患有大血管、仅患有微血管或同时患有大血管和微血管并发症的患者的费用中位数分别是无并发症患者的 3.13 倍、3.79 倍和 10.95 倍。药物支出分别占有并发症和无并发症患者总费用的 51.8%和 79.7%。

结论

尽管每位 2 型糖尿病患者的相关费用相对较低,但它占总费用的很大比例。并发症明显加重了 2 型糖尿病的经济负担。迫切需要适当的管理和预防糖尿病及其并发症,以减轻经济负担。